WJWissal Jame

Wissal Jame

*This is an algorithmically generated author record based on publicly available information.

Wissal Jame has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Bilgen Basgut

    Department of Pharmacology, Baskent University, Ankara, Turkey

    3 shared publications
  • Abdikarim Abdi

    Department of Clinical Pharmacy, Yeditepe University, Istanbul, Turkey

    1 shared publication
  • Abdikarim Abdi

    Department of Clinical Pharmacy, Faculty of Pharmacy Yeditepe University Istanbul Türkiye

    1 shared publication
  • Abdikarim Mohamed Abdi

    Department of Clinical Pharmacy, Faculty of Pharmacy, Near East University, Near East Boulevard P.O.Box: 922022, Nicosia, Northern Cyprus, Mersin10, Turkey

    1 shared publication
  • Hüseyin Kaya Süer

    Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Near East University, Near East Boulevard P.O.Box: 922022, Nicosia, Northern Cyprus, Mersin10, Turkey

    1 shared publication
  • Nedim Çakir

    Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Near East University, Near East Boulevard P.O.Box: 922022, Nicosia, Northern Cyprus, Mersin10, Turkey

    1 shared publication

Latest Publications

  • Open Access

    Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis

    by Wissal Jame, Bilgen Basgut, Abdikarim Abdi

    Objective: To compare between current evidence of novel glycopeptides against vancomycin for the treatment of gram-positive bacterial infections. Methodology: A systematic review and meta-analysis was done. Major databases were searched for eligible randomized control trials that assessed clinical success, microbiological success and safety profile of novel glycopeptides versus vancomycin for infections caused by gram-positive bacteria. Results: This meta-analysis included eleven trials (7289 participants) comparing telavancin, dalbavancin and oritavancin with vancomycin. No differences were detected between novel glycopeptides and vancomycin for the treatment of skin and soft tissue infections (SSTIs) among modified intent-to-treat patients (OR: 1.04, CI: 0.92–1.17) as well as within the clinically evaluable patients (OR: 1.09, CI: 0.91–1.30). Data analysed from SSTIs, HAP and bacteremia studies on telavancin showed insignificant high clinical response in microbiologically evaluable patients infected with methicillin resistant Staphylococcus aureus (MRSA) (OR: 1.57, CI: 0.94–2.62, p: 0.08) and in the eradication of MRSA (OR: 1.39, CI: 0.99–1.96, P:0.06). Dalbavancin was non-inferior to vancomycin for the treatment of osteomyelitis in a phase II trial, while it was superior to vancomycin for the treatment of bacteremia in a phase II trial. Data analysed from all trials showed similar rates of all-cause mortality between compared antibiotics groups (OR: 0.67, CI: 0.11–4.03). Telavancin was significantly related with higher adverse events (OR: 1.24, CI: 1.07–1.44, P: p: 0.01; OR: 0.72, CI: 0.59–0.89, p: <0.01 respectively). Conclusion: Efficacy and safety profiles of both dalbavancin and oritavancin were the same as vancomycin in the treatment of gram-positive bacterial infections in different clinical settings, while telavancin might be an effective alternative to vancomycin in MRSA infections, but caution is required during its clinical use due to the high risk of adverse events, especially nephrotoxicity.


  • Prevalence Study of Antibiotic Usage and Health Care Associated Infections in Northern Cyprus

    by Wissal Jame, Abdikarim Mohamed Abdi, Hüseyin Kaya Süer, Nedim Çakir, Bilgen Basgut

    Purpose: This study aims to provide a prevalence survey of antibiotic usage and HAIs and evaluate the cost of antibiotic therapy. Methods: All inpatients on surgery, paediatrics, medicine, and ICU specialities were surveyed within a period of one week, April 2016 at Near East University hospital in Northern Cyprus. ACross-sectional study was performed and desired data on antibiotic use and HAIs were collected and analysed. Results: Out of 137 inpatients, 39.4% (n=54) were on one or two antibiotics. The usage of antibiotic was appropriate in 70% of the patients while it was inappropriate in the remaining 30%. The most common appropriate use was seen in empirical (80.6%) and prophylaxis (69.2%), while in definitive therapy cases (60.0%), the usage of antibiotics was irrationally inappropriate. Overall, 10.9% of hospitalized patients developed HAI. The most prevalent infection was UTI (urinary tract infections) (33.3%). Prevalence of HAIs was high in patients over 30 years old and in those who stay in hospital more than 10 days. The overall daily cost of antibiotic therapy was $919.61 per day, while the total daily cost for hospital infections was $482. Conclusion: Irrational antibiotic use was seen mostly in definitive therapy, continuous use of empirical therapy without carrying microbiological test was commonly observed. The prevalence of HAI was relatively high which led to more hospitalization and more cost.